US 10232049
Targeted therapeutics
granted A61KA61K31/4196A61K31/454
Quick answer
US patent 10232049 (Targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Grant date
- Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/4196, A61K31/454, A61K31/4745, A61K31/496